Gene-edited crops pioneer Calyxt crashes, giving the lie to deregulation claims
By Jonathan Matthews and Claire Robinson,
GMWatch
| 10. 02. 2022
Kelly Sikkema for Unsplash
As governments around the world are lobbied by industry with claims gene editing can deliver rapid solutions to our food and farming problems — they just need deregulation, the company that pioneered gene-edited crops in the lax regulatory environment of the US is considering selling its assets amid plummeting revenues and share prices.
Calyxt was the first to market gene-edited soybeans in 2019. The beans are genetically engineered to produce high oleic oil. You might think anyone wanting high oleic oils could just buy olive oil but Calyxt was primarily targeting the processed foods markets by promoting its oil as a healthier alternative to commodity soybean oils that produce trans fats when cooked at high temperatures, though no research directly showed health benefits.
Calyxt was also reported to have other “consumer-focused” gene-edited foods in the pipeline, like high fibre wheat and reduced browning potatoes.
Rapidly developing disruptive technology
The company told investors that as a gene editing pioneer accelerating product development, “this is an exciting time for Calyxt and a rapidly developing disruptive plant-based technology story”...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...